# First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis

> **NCT01611688** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 36 (actual)

## Conditions studied

- Inflammation
- Rheumatoid Arthritis

## Interventions

- **DRUG:** NNC0215-0384
- **DRUG:** placebo
- **DRUG:** NNC0215-0384

## Key facts

- **NCT ID:** NCT01611688
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-04
- **Primary completion:** 2013-06-17
- **Final completion:** 2013-06-17
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01611688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01611688, "First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01611688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*